We are excited to announce that Eagle IP has been named as a finalist for the Life Sciences Patent Network (LSPN) Awards USA 2025 in the following categories:   

  1. Inspiring Woman of the Year: This nomination recognizes our President and Managing Director, Ms. Jennifer Che, for her outstanding leadership, innovation, and dedication to empowering others in the industry.  
  1. International Firm of the Year: This nomination recognizes the excellence and achievements of international firms, such as Eagle IP

We are truly honored to be shortlisted in two different categories for the LSPN Awards USA 2025!  This award recognizes "excellence, innovation, and leadership in life sciences IP" and tries to identify individuals and organizations that are "shaping the future of pharmaceutical and biotech patent protection." This recognition is a testament to the hard work and dedication of our entire team. A heartfelt THANK YOU to our clients for your trust and support, to our incredible team for their continued pursuit of excellence, and to our partners for their collaboration. 

You can see all the finalists here

Our Past Events

Recommended Insights

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

9 June 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

4 February 2025
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]

Twice the Trouble: Unraveling a Single Case of Dual Patent and Trademark Infringement

9 January 2024
Can a rights holder sue the same infringer separately based on one single infringing act that infringes both trademark and patent rights? An interesting case this year from China’s Supreme People’s Court that addresses this specific issue ((2023)最高法知民终235号). Beijing Run De Hong Tu Technology Development Co., Ltd. (“Run De Hong Tu”) sued an individual named […]

Diagnostic Claims in China

9 January 2020
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
Top crossarrow-right